Friday 6 November 2026 Export RLAY’s income statement to Excel — free account

Relay Therapeutics, Inc.

Relay Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $15.4 million, up 53.4% from fiscal 2024.

Revenue: −95.4%
EPS: 0.00%
Free cash flow: +2.13%

Quarter to June 2026, against a year earlier

18.44 1.44 +8.47%

Follow RLAY

Alert me

Market cap: $3.7B
P/E: 0.0×
Fwd P/E: −11.4×
Dividend yield: —
F-score: 5/9
Altman Z: 10.99
Beneish M: n/a
Dividend safety: n/a

Overview

Relay Therapeutics, Inc. (RLAY) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Relay Therapeutics, Inc. (RLAY) trades at a P/S ratio of 313×. Over the past ten years it has ranged from 0.0× (September 2021) to 1,866× (April 2023); the current reading is higher than 67% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/RLAY/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Relay Therapeutics, Inc. P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/RLAY/metrics/ps-ratio">Relay Therapeutics, Inc. (RLAY) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	57.2×	243.52%
FY2024	16.7×	(70.72%)
FY2023	56.9×	(95.34%)
FY2022	1,222×	26.72%
FY2021	965×	—
FY2020	0.0×	—

Period	P/S ratio	Change
Jun 2026	344×	253.06%
Mar 2026	97.5×	70.34%
Dec 2025	57.2×	77.36%
Jun 2025	32.3×	212.15%
15 more quarters	Free account

Against its own ten years

Low 0.0× High 1,866×

Ten-year median 41.6×

Current reading's percentile 59

Company	P/S ratio
PBLS Parabilis Medicines, Inc. compare	n/m
EWTX Edgewise Therapeutics, Inc. compare	n/m
IRON Disc Medicine, Inc. compare	n/m
ACAD ACADIA Pharmaceuticals Inc. compare	3.1×
IOVA Iovance Biotherapeutics, Inc. compare	9.3×
TNGX Tango Therapeutics, Inc. compare	51.0×
ABCL AbCellera Biologics Inc. compare	51.9×
XENE Xenon Pharmaceuticals Inc. compare	223×
RLAY Relay Therapeutics, Inc.	313×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Relay Therapeutics, Inc. (RLAY) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on RLAY

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on RLAY

Stockrow Weekly